Countries in which
    Products are registered
 
 
 
 Countries in which
    Products are under
    resgistration

 
 
 Countries which follow
     WHO-GMP guidelines

 
International.
 
 
KLab has presence in 23 countries having registered more than 50 products and more than 200 Dossiers are under registration.
 
 Regulated Markets (USA, EUROPE)
 
 
 
KLab is under negotiation of outlicensing its Patented Products based
   on NDDS, Nanotechnology, Dendrimers and Chiral Chemistry.

 Non-Regulated Market (SOUTH EAST, ASIA, AFRICA, LATIN    
 AMERICA,
 CIS ETC)
 

 
WHO-GMP Approved manufacturing facilities for Oncology, General
   tablets and cephalosporin.
 
Presently, KLab has operations in Nigeria, Ethiopia, Kenya, Ghana, Zambia, Mozambique, Ivory Coast, Haiti, Dominican Republic, Trinidad & Tobago, Iraq, Georgia, Guatemala, Honduras, Myanmar, Thailand, Philippines, Hong Kong, Cambodia, Vietnam, Sri Lanka, Maldives.
 
KLab expects to have its presence in Costa Rica, Ecuador, Chile, Venezuela, Bolivia, Uganda, Tanzania, Yemen, Oman, Jordan, Syria, Cameroon, Benin, South Africa, Pakistan, Bhutan, Indonesia and Malaysia in near future, wherein number of products are due for registration.

WHO-GMP Approved manufacturing facilities

WHO-GMP Approved manufacturing facilities for Oncology, General tablets and cephalosporin.

  

Markets

Non-Regulated
(SOUTH EAST, ASIA, AFRICA, LATIN    
AMERICA, CIS ETC)

 

 
We are supplying our niche oncology Products to several countries as also are under negotiation to manufacture for various overseas companies.  
We are negotiating new arrangements for our new NDDS Formulations for which we have applied for Product Patents

 
   
© 2001 - 2007 Khandelwal Laboratories Pvt.Ltd. All rights reserved.